Novo Nordisk A/S (NYSE:NVO) Trading Down 6.1% – Here’s Why

Novo Nordisk A/S (NYSE:NVO) dropped 6.1% during mid-day trading on Tuesday . The stock traded as low as $43.80 and last traded at $44.2390. 17,950,368 shares changed hands during trading, a decline of 0% from the average session volume of 17,988,822 shares. The stock had previously closed at $47.09.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q2 results exceeded expectations: Adjusted sales rose 7% at constant exchange rates to DKK 178.5 billion, while adjusted operating profit increased 11% to DKK 33.4 billion. Reported EPS of $0.96 surpassed the $0.77 consensus estimate. Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
• Positive Sentiment: Management raised its full-year outlook: Novo Nordisk narrowed the expected 2026 decline in adjusted sales and operating profit, citing GLP-1 volume growth, demand for the higher-dose Wegovy injection and favorable U.S. rebate adjustments. Novo Nordisk’s Q2 profit beats forecasts, raises outlook
• Positive Sentiment: Oral Wegovy is gaining traction: The weight-loss pill has exceeded 5 million U.S. prescriptions since launch, supporting optimism that it can expand Novo Nordisk’s obesity-drug franchise. Novo Nordisk Q2 2026 earnings beat, raises full-year outlook
• Neutral Sentiment: Novo Nordisk is studying real-world GLP-1 users to assess potential thyroid-cancer risks. The update concerns an ongoing database study and does not establish a new safety signal. Novo Nordisk Probes Thyroid Cancer Risk in Real-World GLP-1 Users
• Negative Sentiment: Sales momentum disappointed relative to lofty expectations: Investors focused on softer-than-anticipated Wegovy pill sales, while reported operating profit declined because of prior-year U.S. rebate effects. Novo also faces intense competition from Eli Lilly’s Mounjaro and Zepbound. Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes
• Negative Sentiment: The failure of the late-stage ZEUS trial for heart drug candidate zilte…kimab weakened the case for diversifying beyond GLP-1 medicines and added to investor concerns about Novo Nordisk’s pipeline. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Analyst Ratings Changes

Several brokerages recently weighed in on NVO. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

The stock’s 50 day moving average price is $46.96 and its 200 day moving average price is $45.32. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $197.18 billion, a PE ratio of 10.37, a P/E/G ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently modified their holdings of NVO. Platform Technology Partners grew its stake in shares of Novo Nordisk A/S by 39.2% in the second quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock valued at $525,000 after buying an additional 3,079 shares in the last quarter. Fortis Group Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 145.5% during the 2nd quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock valued at $3,496,000 after buying an additional 43,213 shares during the period. Allen Wealth Management LLC acquired a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $205,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $2,324,000. Finally, Avidian Wealth Enterprises LLC boosted its holdings in Novo Nordisk A/S by 17.5% in the 2nd quarter. Avidian Wealth Enterprises LLC now owns 31,634 shares of the company’s stock worth $1,517,000 after acquiring an additional 4,708 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.